Youwendu Bioengineering operates dual‑region entities in Henan and Shenzhen. It is a high‑end regenerative‑medicine technology enterprise focusing on the R&D, compliant manufacturing and clinical translation of stem cell, immune cell and super‑vesicle technologies. Rooted in two exclusive core technologies — super‑vesicle technology and multi‑target regulatory T‑cell (Treg) immune modulation, the company follows clinical efficacy‑oriented principles and compliance‑driven operation standards. It builds in‑depth industry‑academia‑medical cooperation platforms to accelerate the precise clinical implementation of cutting‑edge cell‑based technologies.
The core team brings together top‑tier talents from home and abroad. Founder Dr. Rong Xin holds a degree from Daito Bunka University in Japan. During his overseas study and professional career, he founded Japanese corporation Koshinen Co., Ltd. With more than ten‑year experience in overseas large‑scale health‑service industries, he has served thousands of clients from China for premium health‑management programs including early‑stage cancer screening, regenerative‑medicine anti‑aging intervention and chronic‑disease conditioning, building profound expertise in overseas health‑industry operation and project delivery. After returning to China, he served as General Manager of Henan Region at Zhongyuan Concord Cell & Genetic Engineering Co., Ltd. He maintains sharp insight into domestic cell‑industry policies and regulatory requirements, and has successfully delivered multiple cell‑technology translation projects with outstanding capabilities in industry‑resource integration and clinical‑program coordination.
Chief Scientist Professor Zhang Haiying holds a medical doctorate from the Chinese PLA General Hospital (301 Hospital), professorship at the Academy of Military Medical Sciences, postdoctoral fellowship at the University of Hong Kong, and senior research fellowship at Queen Mary Hospital, Hong Kong. Under his leadership, the company independently develops and masters two core technologies: super‑vesicle technology and multi‑target Treg immune‑modulation technology. Leveraging advanced R&D strengths, the team has overcome multiple technical bottlenecks in cell‑based applications and achieved breakthrough outcomes for autoimmune and degenerative diseases, delivering solid technical support for in‑house R&D and clinical investigations.
The robust R&D team consists of 10 specialized researchers, including 4 PhD holders and 6 talents with master’s or higher degrees, forming a highly‑educated, professional and experienced R&D echelon to drive continuous technical iteration and product innovation. A dedicated health‑management department is staffed by 6 professionals (2 with master’s degrees and 4 with bachelor’s degrees), forming a high‑caliber service team to deliver full‑cycle and refined health‑management services for clients.
For quality and safety control, the company adheres to high‑standard R&D workflows. Pre‑clinical preliminary studies have been completed with sufficient safety verification, and formal animal trials are well underway. As one of the few domestic biotech enterprises conducting systematic animal studies, the company safeguards the safety and reliability of its technologies and formulations from the source. A rigorous quality‑control system is implemented: every batch of super‑vesicle products undergoes full testing before release with full‑process traceability, establishing a solid safety foundation for clinical research and applications.
Backed by its two core technologies and mature medical‑research resources, the company accumulates solid clinical‑translation experience. Led by Chief Scientist Professor Zhang Haiying, a clinical research collaboration has been launched with The Second Affiliated Hospital of Zhengzhou University in the Department of Cardiovascular Medicine. The clinical effective rate for coronary heart disease reaches over 83 %, proving the safety and efficacy of the technology via authoritative Grade‑A tertiary hospital validation. Substantial real‑world clinical cases and supporting video evidence have demonstrated promising outcomes for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), as well as cognitive‑impairment improvement.
Furthermore, drawing on super‑vesicle and multi‑target Treg immune‑modulation technologies, the company expands its footprint across high‑demand clinical areas including female reproductive anti‑aging, male reproductive anti‑aging, autoimmune disorders and bone‑joint repair. A multi‑track, multi‑indication technical‑application matrix is established, supported by complete clinical‑research protocols, real‑world efficacy datasets and end‑to‑end operational experience.
Going forward, the company will further deepen regenerative‑medicine clinical translation and strictly abide by domestic medical‑compliance policies. By partnering with tertiary hospitals and medical specialists nationwide, it will advance investigator‑initiated trials (IIT) for stem‑cell and exosome‑related technologies covering cardiovascular‑cerebrovascular conditions, neurodegenerative diseases, reproductive health, bone‑joint disorders and autoimmune illnesses. It aims to realize standardized, evidence‑based and clinically‑oriented deployment of state‑of‑the‑art biotechnologies and contribute to medical advancement and patient wellbeing.
